Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dexmedetomidine During Weaning From Analgesia and Sedation in PICU (TIP-15-01)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Continuous analgesic and sedative endovenous treatment for at least 5 days~* Invasive or non-invasive mechanical ventilation~* Clinical conditions that allow by clinical judgment the start of analgosedation weaning~* Post-natal age ≥ 7 days and PMA beyond the 37 weeks~* Written informed consent obtained~Exclusion Criteria:~* Hemodynamic instability~* Cardiac bundle-branch block of 2 or 3 degree~* Hypersensitivity to the alpha-agonists~* Persistent fever of unknown origin or sensitivity to malignant hyperthermia~* Use of alpha-agonist (clonidine or dexmedetomidine) in the last 30 days

- Gender: ALL
- Minimum Age: 7 Days
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): Dexmedetomidine 100 mcg/ml concentrate solution. Continuous iv infusion. Start dose 0.4 mcg/kg/h, increases by 0.2 mcg/kg/h until 0.8 mcg/kg/h (half dose for neonates). If withdrawal symptoms appear the dose can be increased to a maximum of 1.4 mcg/Kg/h.
- Placebo (Type: PLACEBO_COMPARATOR): saline solution for IV infusion. The administration of infusion will follow the experimental drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).